Pre-clinical Data From ReNeuron With ReN004 Human Stem Cell Lines For Parkinson's Disease
Related News: Spinal / Nervous / BrainReNeuron Group plc has announced that initial testing of its candidate stem cell lines, ReN004, proved to have attributes that may help fixing the neurological deficits seen in Parkinson's disease.
C-mycERTAM stem cell expansion technology was used to generate the human cell lines, which were pre-screened for both genetic stability and their ability to differentiate into tyrosine hydroxylase (TH)- a marker for a dopaminergic stem cell phenotype.
This cell type is deficient in patients suffering from Parkinson's disease.
All of the cell lines showed good survival four weeks post-implantation into the appropriate regions of the rodent brain.
Dr John Sinden, Chief Scientific Officer of ReNeuron, said that they're "greatly encouraged by these early results with our ReN004 programme for Parkinson's disease."
ReNeuron has used its c-mycERTAM technology to generate genetically stable neural stem cell lines. This technology platform has multi-national patent protection and is fully regulated by means of a chemically-induced safety switch. Cell growth can therefore be completely arrested prior to in vivo implantation.
Source: ReNeuron
Posted on February 23, 2006 11:55 AM